Join
Live feed
·
PRReleasevia Quantisnow
Theravance Biopharma Inc. logo

Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis

ByQuantisnow·Wall Street's wire, on your screen.
TBPH· Theravance Biopharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TBPH (Theravance Biopharma Inc.) and more on Quantisnow.